RAPT Therapeutics’ (RAPT) Buy Rating Reaffirmed at HC Wainwright

RAPT Therapeutics (NASDAQ:RAPT)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $10.00 target price on the stock. HC Wainwright also issued estimates for RAPT Therapeutics’ FY2026 earnings at ($0.91) EPS.

Several other research firms have also recently issued reports on RAPT. Wells Fargo & Company lowered their price objective on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $2.00 price objective (down from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. JPMorgan Chase & Co. cut RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a report on Monday, November 11th. Finally, Piper Sandler cut RAPT Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $8.00 to $2.00 in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $5.29.

RAPT Therapeutics Stock Up 6.5 %

RAPT Therapeutics stock opened at $1.14 on Monday. The company has a market capitalization of $39.85 million, a P/E ratio of -0.41 and a beta of -0.31. The stock’s 50 day moving average is $1.23 and its 200 day moving average is $1.53. RAPT Therapeutics has a twelve month low of $0.79 and a twelve month high of $9.65.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings data on Thursday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.69). As a group, equities analysts expect that RAPT Therapeutics will post -2.14 EPS for the current year.

Institutional Investors Weigh In On RAPT Therapeutics

Institutional investors have recently bought and sold shares of the business. Barclays PLC increased its stake in RAPT Therapeutics by 277.2% in the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after buying an additional 29,195 shares in the last quarter. SG Americas Securities LLC grew its position in shares of RAPT Therapeutics by 401.9% during the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock valued at $84,000 after purchasing an additional 42,636 shares in the last quarter. Los Angeles Capital Management LLC grew its position in shares of RAPT Therapeutics by 138.1% during the third quarter. Los Angeles Capital Management LLC now owns 201,439 shares of the company’s stock valued at $405,000 after purchasing an additional 116,853 shares in the last quarter. Medicxi Ventures Management Jersey Ltd purchased a new position in shares of RAPT Therapeutics during the fourth quarter valued at about $35,316,000. Finally, Readystate Asset Management LP purchased a new position in shares of RAPT Therapeutics during the third quarter valued at about $36,000. Hedge funds and other institutional investors own 99.09% of the company’s stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.